First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient

Loading Curie Briefs...

Getting the latest healthcare news for you

First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient | Curie Briefs

First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient

6 days ago•Healio

Summary

A kidney transplant patient with a rare, drug-resistant bacterial condition was successfully treated with an engineered bacteriophage cocktail — a first in human medicine. The patient's abdominal mass shrank 50% in 8 weeks and 89% at one year. Researchers say the case is a promising proof-of-concept for phage therapy when antibiotics fail.

First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient

A 65-year-old kidney transplant recipient developed malakoplakia — a rare inflammatory condition — after battling chronic, multidrug-resistant E. coli infections. Despite aggressive antibiotic therapy, his condition kept worsening, eventually producing a large intra-abdominal mass. Physicians turned to SNIPR001, an engineered bacteriophage cocktail, administered under the FDA's single-patient emergency investigational new drug designation.

The results were striking. External lesions began improving within a week, and the abdominal mass shrank by 50% at 8 weeks and 89% at one year. The phage cocktail was delivered three ways: intravenously, topically, and via direct injection into the mass — alongside IV antibiotics.

Key Takeaways:

Phage therapy may be a viable adjunct when antimicrobial resistance limits conventional options
Controlled studies are still needed to isolate the specific contribution of phages vs. antibiotics
FDA's emergency IND pathway enabled access to this novel therapy for a single patient

Why it matters: With antibiotic resistance on the rise, this case offers an encouraging proof-of-concept that engineered phages could fill a critical gap in treating severe, persistent bacterial infections — especially in immunocompromised patients.

Curie Brief

Loading Curie Briefs...

Curie Brief

Curie Brief

First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient

Summary

First-in-human engineered phage cocktail beats drug-resistant infection in transplant patient

Related stories

Pennsylvania measles deaths are the first US fatalities of 2026 — and experts say they were entirely preventable

Vaccine package inserts list reported events — not proven harms. Here's why that distinction matters.

Medical societies push Congress for a $20B investment to close the women's health gap